Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

[Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial].

Aver'ianov AV, Babkin AP, Bart BIa, Volchetskiĭ AL, Minina ES, Kozyrev OA, Kostinov MP, Petrov DV, Sel'kova EP, Putilovskiĭ MA, Nechaev VB, Epshteĭn OI, Andrianova EN.

Antibiot Khimioter. 2012;57(7-8):23-30. Russian.

PMID:
23350191
2.

[Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].

Geppe NA, Kondiurina EG, Galustian AN, Pak TE, Bal'tserovich NB, Zhiglinskaia OV, Kamaev AV, Lazareva SG, Laléko SL, Mel'nikova IM, Perminova OA, Sabitov AU.

Antibiot Khimioter. 2014;59(5-6):6-14. Russian.

PMID:
25552038
3.

Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial.

Rafalsky V, Averyanov A, Bart B, Minina E, Putilovskiy M, Andrianova E, Epstein O.

Int J Infect Dis. 2016 Oct;51:47-55. doi: 10.1016/j.ijid.2016.09.002. Epub 2016 Sep 8.

4.

Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice.

Skarnovich MA, Emelyanova AG, Petrova NV, Borshcheva AA, Gorbunov EA, Mazurkov OY, Skarnovich MO, Tarasov SA, Shishkina LN, Epstein OI.

Antivir Ther. 2017;22(4):345-351. doi: 10.3851/IMP3115. Epub 2016 Dec 7.

PMID:
27924780
5.

[Pandemic influenza in Russia: specific features of clinical course and the absence of early etiotropic therapy as a risk factor of severe forms of the disease].

Kolobukhina LV, Merkulova LN, Shchelkanov MIu, Burtseva EI, Lavrishcheva VV, Samokhvalov EI, Al'khovskiĭ SV, Prilipov AG, Proshina ES, Avdeev SN, Sutochnikova OA, Bazarova MV, Kelli EI, Tserukalova ND, Blank IA, Shestakova OM, Kolivashko ON, Arseneva TV, Ambrosi OE, Shul'diakov AA, Popov AF, Simakova AI, Malyshev NA, Chuchalin AG, L'vov DK.

Ter Arkh. 2011;83(9):48-53. Russian.

PMID:
22145388
6.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.

Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ.

Cochrane Database Syst Rev. 2014 Apr 10;(4):CD008965. doi: 10.1002/14651858.CD008965.pub4. Review.

PMID:
24718923
7.

Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China.

Yu H, Liao Q, Yuan Y, Zhou L, Xiang N, Huai Y, Guo X, Zheng Y, van Doorn HR, Farrar J, Gao Z, Feng Z, Wang Y, Yang W.

BMJ. 2010 Sep 28;341:c4779. doi: 10.1136/bmj.c4779.

8.

Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial.

Duan ZP, Jia ZH, Zhang J, Liu S, Chen Y, Liang LC, Zhang CQ, Zhang Z, Sun Y, Zhang SQ, Wang YY, Wu YL.

Chin Med J (Engl). 2011 Sep;124(18):2925-33.

PMID:
22040504
9.

[Efficacy and safety of oseltamivir in children with suspected influenza: a multicenter randomized open-label trial].

He CH, Liu CY, Lin GY, Peng Q, Liao JY, Lin JH, Zhang T, Zheng XF, Lin CX, Wang SJ, Chen RS, Deng L, Chen YM.

Zhonghua Er Ke Za Zhi. 2017 Jun 2;55(6):462-467. doi: 10.3760/cma.j.issn.0578-1310.2017.06.014. Chinese.

PMID:
28592016
10.

Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.

Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, Azim T, Bresee J, Luby SP, Brooks WA.

Lancet Infect Dis. 2014 Feb;14(2):109-18. doi: 10.1016/S1473-3099(13)70267-6. Epub 2013 Nov 22.

PMID:
24268590
11.

Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.

Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, Gu L, Dong JP, Liang LR, Li XW, Hu K, He XS, Sun YH, An Y, Yang T, Cao ZX, Guo YM, Wen XM, Wang YG, Liu YL, Jiang LD.

Ann Intern Med. 2011 Aug 16;155(4):217-25. doi: 10.7326/0003-4819-155-4-201108160-00005. Erratum in: Ann Intern Med. 2012 Jan 3;156(1 Pt 1):71.

PMID:
21844547
12.

Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia.

Leneva IA, Burtseva EI, Yatsyshina SB, Fedyakina IT, Kirillova ES, Selkova EP, Osipova E, Maleev VV.

Int J Infect Dis. 2016 Feb;43:77-84. doi: 10.1016/j.ijid.2016.01.001. Epub 2016 Jan 9.

13.

Antiviral drugs in influenza: an adjunct to vaccination in some situations.

[No authors listed]

Prescrire Int. 2006 Feb;15(81):21-30.

PMID:
16548114
14.

[A multicenter randomized controlled study of the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population].

Lin JT, Yu XZ, Cui DJ, Chen XY, Zhu JH, Wang YZ, Wu XD, Gao H, Huo ZL, Zhu SH, Hu SL, Wang AX.

Zhonghua Jie He He Hu Xi Za Zhi. 2004 Jul;27(7):455-9. Chinese.

PMID:
15312558
15.

Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.

Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, Mitamura K.

Clin Infect Dis. 2008 Aug 1;47(3):339-45. doi: 10.1086/589748.

PMID:
18582202
16.

Comparison of efficacy and safety of oseltamivir and zanamivir in pandemic influenza treatment.

Tuna N, Karabay O, Yahyaoğlu M.

Indian J Pharmacol. 2012 Nov-Dec;44(6):780-3. doi: 10.4103/0253-7613.103301.

17.

Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).

Wang K, Shun-Shin M, Gill P, Perera R, Harnden A.

Cochrane Database Syst Rev. 2012 Apr 18;(4):CD002744. doi: 10.1002/14651858.CD002744.pub4. Review.

PMID:
22513907
18.

Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.

Beigel JH, Bao Y, Beeler J, Manosuthi W, Slandzicki A, Dar SM, Panuto J, Beasley RL, Perez-Patrigeon S, Suwanpimolkul G, Losso MH, McClure N, Bozzolo DR, Myers C, Holley HP Jr, Hoopes J, Lane HC, Hughes MD, Davey RT; IRC003 Study Team.

Lancet Infect Dis. 2017 Dec;17(12):1255-1265. doi: 10.1016/S1473-3099(17)30476-0. Epub 2017 Sep 22.

PMID:
28958678
19.

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG.

JAMA. 2000 Feb 23;283(8):1016-24.

PMID:
10697061
20.

Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.

Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, Liang ZA, Liang L, Zhang SJ, Zhang B, Gu L, Lu LH, Wang DY, Wang C; National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China.

N Engl J Med. 2009 Dec 24;361(26):2507-17. doi: 10.1056/NEJMoa0906612. Epub 2009 Dec 9.

Supplemental Content

Support Center